학술논문

Mutations in EBF3 Disturb Transcriptional Profiles and Cause Intellectual Disability, Ataxia, and Facial Dysmorphism
Document Type
article
Source
American Journal of Human Genetics. 100(1)
Subject
Biological Sciences
Bioinformatics and Computational Biology
Genetics
Human Genome
Biotechnology
Brain Disorders
Intellectual and Developmental Disabilities (IDD)
Pediatric
2.1 Biological and endogenous factors
Aetiology
Generic health relevance
Adolescent
Adult
Amino Acid Substitution
Ataxia
Child
Child
Preschool
Chromatin
Cyclin-Dependent Kinase Inhibitor p21
Developmental Disabilities
Exome
Face
Female
Gene Expression Regulation
Genes
Reporter
HEK293 Cells
Humans
Intellectual Disability
Language Development Disorders
Male
Models
Molecular
Mosaicism
Mutation
Neurodevelopmental Disorders
Protein Transport
Syndrome
Transcription Factors
Transcription
Genetic
EBF3
de novo mutation
developmental delay
gene regulation
intellectual disability
transcription factor
Medical and Health Sciences
Genetics & Heredity
Biological sciences
Biomedical and clinical sciences
Health sciences
Language
Abstract
From a GeneMatcher-enabled international collaboration, we identified ten individuals affected by intellectual disability, speech delay, ataxia, and facial dysmorphism and carrying a deleterious EBF3 variant detected by whole-exome sequencing. One 9-bp duplication and one splice-site, five missense, and two nonsense variants in EBF3 were found; the mutations occurred de novo in eight individuals, and the missense variant c.625C>T (p.Arg209Trp) was inherited by two affected siblings from their healthy mother, who is mosaic. EBF3 belongs to the early B cell factor family (also known as Olf, COE, or O/E) and is a transcription factor involved in neuronal differentiation and maturation. Structural assessment predicted that the five amino acid substitutions have damaging effects on DNA binding of EBF3. Transient expression of EBF3 mutant proteins in HEK293T cells revealed mislocalization of all but one mutant in the cytoplasm, as well as nuclear localization. By transactivation assays, all EBF3 mutants showed significantly reduced or no ability to activate transcription of the reporter gene CDKN1A, and in situ subcellular fractionation experiments demonstrated that EBF3 mutant proteins were less tightly associated with chromatin. Finally, in RNA-seq and ChIP-seq experiments, EBF3 acted as a transcriptional regulator, and mutant EBF3 had reduced genome-wide DNA binding and gene-regulatory activity. Our findings demonstrate that variants disrupting EBF3-mediated transcriptional regulation cause intellectual disability and developmental delay and are present in ∼0.1% of individuals with unexplained neurodevelopmental disorders.